Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2013

Open Access 01-10-2013 | Research article

Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways

Authors: Amy L Strong, Thomas A Strong, Lyndsay V Rhodes, Julie A Semon, Xiujuan Zhang, Zhenzhen Shi, Shijia Zhang, Jeffrey M Gimble, Matthew E Burow, Bruce A Bunnell

Published in: Breast Cancer Research | Issue 5/2013

Login to get access

Abstract

Introduction

Obesity has been associated with increased incidence and mortality of breast cancer. While the precise correlation between obesity and breast cancer remains to be determined, recent studies suggest that adipose tissue and adipose stem cells (ASCs) influence breast cancer tumorigenesis and tumor progression.

Methods

Breast cancer cells lines were co-cultured with ASCs (n = 24), categorized based on tissue site of origin and body mass index (BMI), and assessed for enhanced proliferation, alterations in gene expression profile with PCR arrays, and enhanced tumorigenesis in immunocompromised mice. The gene expression profile of ASCs was assess with PCR arrays and qRT-PCR and confirmed with Western blot analysis. Inhibitory studies were conducted by delivering estrogen antagonist ICI182,780, leptin neutralizing antibody, or aromatase inhibitor letrozole and assessing breast cancer cell proliferation. To assess the role of leptin in human breast cancers, Oncomine and Kaplan Meier plot analyses were conducted.

Results

ASCs derived from the abdominal subcutaneous adipose tissue of obese subjects (BMI > 30) enhanced breast cancer cell proliferation in vitro and tumorigenicity in vivo. These findings were correlated with changes in the gene expression profile of breast cancer cells after co-culturing with ASCs, particularly in estrogen receptor-alpha (ESR1) and progesterone receptor (PGR) expression. Analysis of the gene expression profile of the four groups of ASCs revealed obesity induced alterations in several key genes, including leptin (LEP). Blocking estrogen signaling with ICI182,780, leptin neutralizing antibody, or letrozole diminished the impact of ASCs derived from obese subjects. Women diagnosed with estrogen receptor/progesterone receptor positive (ER+/PR+) breast cancers that also expressed high levels of leptin had poorer prognosis than women with low leptin expression.

Conclusion

ASCs isolated from the abdomen of obese subjects demonstrated increased expression of leptin, through estrogen stimulation, which increased breast cancer cell proliferation. The results from this study demonstrate that abdominal obesity induces significant changes in the biological properties of ASCs and that these alterations enhance ER+/PR+ breast cancer tumorigenesis through estrogen dependent pathways.
Appendix
Available only for authorised users
Literature
1.
Cleary M, Maihle N: The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997, 216: 28-43. 10.3181/00379727-216-44153B.CrossRefPubMed
2.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348: 1625-1638. 10.1056/NEJMoa021423.CrossRefPubMed
3.
Ahn J, Schatzkin A, Lacey JV, Albanes D, Ballard-Barbash R, Adams KF, Kipnis V, Mouw T, Hollenbeck AR, Leitzmann MF: Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007, 167: 2091-2102. 10.1001/archinte.167.19.2091.CrossRefPubMed
4.
Eliassen A, Colditz G, Rosner B, Willett W, Hankinson S: Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006, 296: 193-201. 10.1001/jama.296.2.193.CrossRefPubMed
5.
Sestak I, Distler W, Forbes J, Dowsett M, Howell A, Cuzick J: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010, 28: 3411-3415. 10.1200/JCO.2009.27.2021.CrossRefPubMed
6.
Carmichael A: Obesity and prognosis of breast cancer. Obes Rev. 2006, 7: 333-340. 10.1111/j.1467-789X.2006.00261.x.CrossRefPubMed
7.
Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, Coldman AJ, Potter JD, Gallagher RP, Hislop TG: Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol. 2003, 158: 963-968. 10.1093/aje/kwg236.CrossRefPubMed
8.
Kumar NB, Cantor A, Allen K, Cox CE: Android obesity at diagnosis and breast carcionma survival: evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer. 2000, 88: 2751-2757. 10.1002/1097-0142(20000615)88:12<2751::AID-CNCR13>3.0.CO;2-1.CrossRefPubMed
9.
Pinilla P, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, Song YH: Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer invasion. Cancer Lett. 2009, 284: 80-85. 10.1016/j.canlet.2009.04.013.CrossRefPubMed
10.
Walter M, Liang S, Ghosh S, Hornsby PJ, Li R: Interleukin 6 secreted from adipose stromal cells promotes migration and invasioin of breast cancer cells. Oncogene. 2009, 28: 2745-2755. 10.1038/onc.2009.130.CrossRefPubMedPubMedCentral
11.
Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini F: Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE. 2012, 7: e30563-10.1371/journal.pone.0030563.CrossRefPubMedPubMedCentral
12.
Karp J, Teo G: Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009, 4: 206-216. 10.1016/j.stem.2009.02.001.CrossRefPubMed
13.
Zhang Y, Daquinag AC, Amaya-Manzanares F, Sirin O, Tseng C, Kolonin MG: Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res. 2012, 72: 5198-5208. 10.1158/0008-5472.CAN-12-0294.CrossRefPubMed
14.
Muehlberg FL, Song YH, Krohn A, Pinillia SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU: Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis. 2009, 30: 589-597. 10.1093/carcin/bgp036.CrossRefPubMed
15.
Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, Kishnappa S, Pinilla S, Droll L, Song YH: Adipose tissue derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor derived factors. Cell Oncol. 2011, 34: 55-67.CrossRef
16.
Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, Gurav K, Tran K-V, Straubhaar J, Nicoloro S, Czech MP, Thompson M, Perugini RA, Corvera S: Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation. 2011, 123: 186-194. 10.1161/CIRCULATIONAHA.110.970145.CrossRefPubMedPubMedCentral
17.
Strong AL, Semon JA, Strong TA, Santoke TT, Zhang S, McFerrin HE, Gimble JM, Bunnell BA: Obesity-associated dysregulation of calpastatin and MMP-15 in adipose-derived stromal cells results in their enhanced invasion. Stem Cells. 2012, 30: 2774-2783. 10.1002/stem.1229.CrossRefPubMed
18.
Yu G, Floyd E, Wu X, Halvorsen Y-D, Gimble JM: Isolation of human adipose-derived stem cells from lipoaspirates. Methods Mol Biol. 2011, 702: 17-27. 10.1007/978-1-61737-960-4_2.CrossRefPubMed
19.
Yu G, Wu X, Dietrich MA, Polk P, Scott LK, Ptitsyn AA, Gimble JM: Yield and characterization of subcutaneous human adipose-derived stem cells by flow cytometric and adipogenic mRNA analyzes. Cytotherapy. 2010, 12: 538-546. 10.3109/14653241003649528.CrossRefPubMedPubMedCentral
20.
Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010, 121: 293-300. 10.1007/s10549-009-0458-2.CrossRefPubMed
21.
Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010, 123: 725-731. 10.1007/s10549-009-0674-9.CrossRefPubMed
22.
Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P, Muller C: Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011, 71: 2455-2465. 10.1158/0008-5472.CAN-10-3323.CrossRefPubMed
23.
Rehrer CW, Karimpour-Fard A, Hernandez TL, Law CK, Stob NR, Hunter LE, Eckel RH: Regional differences in subcutaneous adipose tissue gene expression. Obesity. 2012, 20: 2168-2173. 10.1038/oby.2012.117.CrossRefPubMedPubMedCentral
24.
Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X, Shang Y: Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004, 64: 5870-5875. 10.1158/0008-5472.CAN-04-0655.CrossRefPubMed
25.
Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP: Effects of adipnectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep. 2009, 21: 1611-1619.PubMed
26.
Fusco R, Galgani M, Procaccini C, Franco R, Pirozzi G, Fucci L, Laccetti P, Matarese G: Cellular and molecular crosstalk between leptin receptor and estrogen receptor-alpha in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer. 2010, 17: 373-382. 10.1677/ERC-09-0340.CrossRefPubMed
27.
Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Ando S: Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003, 278: 28668-28676. 10.1074/jbc.M301695200.CrossRefPubMed
28.
Gonzalez RR, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11: R36-10.1186/bcr2321.CrossRef
29.
Cleland W, Mendelson C, Simpson E: Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab. 1985, 60: 174-177. 10.1210/jcem-60-1-174.CrossRefPubMed
30.
Kars M, Iseri O, Gunduz U: A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. Eur J Pharmacol. 2011, 657: 4-9. 10.1016/j.ejphar.2011.02.001.CrossRefPubMed
31.
Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ: Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem. 1999, 75: 424-436. 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8.CrossRefPubMed
32.
Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison WO, Halvorsen YD, Gimble JM: Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. J Cell Biochem. 2001, 81: 312-319. 10.1002/1097-4644(20010501)81:2<312::AID-JCB1046>3.0.CO;2-Q.CrossRefPubMed
33.
Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006, 12: 1447-1453. 10.1158/1078-0432.CCR-05-1913.CrossRefPubMed
34.
Caldefie-Chézet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Guerry M, Penault-Llorca F, Guillot J, Vasson MP: Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun. 2005, 334: 737-741. 10.1016/j.bbrc.2005.06.077.CrossRefPubMed
Metadata
Title
Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways
Authors
Amy L Strong
Thomas A Strong
Lyndsay V Rhodes
Julie A Semon
Xiujuan Zhang
Zhenzhen Shi
Shijia Zhang
Jeffrey M Gimble
Matthew E Burow
Bruce A Bunnell
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3569

Other articles of this Issue 5/2013

Breast Cancer Research 5/2013 Go to the issue

Viewpoint

Pregnancy offers new insights into mechanisms of breast cancer risk and resistance

Research article

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women

Research article

Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development

Research article

Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillanceby Enhancing Intratumoral Immune Checkpoint Activity

Research article

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Research article

Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits